{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:25:41Z","timestamp":1791890741337,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.prrv.2019.08.002","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:32:45Z","timestamp":1570649565000},"page":"118-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"special_numbering":"C","title":["Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes"],"prefix":"10.1016","volume":"36","author":[{"given":"Melissa D.","family":"Gans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Gavrilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2019.08.002_b0005","unstructured":"National Center for Health Statistics. National Health Interview Survey, 2016. Public-use data file and documentation. http:\/\/www.cdc.gov\/nchs\/nhis\/quest_data_related_1997_forward.htm. 2018."},{"key":"10.1016\/j.prrv.2019.08.002_b0010","series-title":"Global initiative for asthma: global strategy for asthma management and prevention (2016 update)","year":"2016"},{"issue":"2","key":"10.1016\/j.prrv.2019.08.002_b0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"Lotvall","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"83","key":"10.1016\/j.prrv.2019.08.002_b0020","first-page":"243","article-title":"Asthma phenotypes and endotypes: an evolving paradigm for classification","volume":"15","author":"Corren","year":"2013","journal-title":"Discov Med"},{"key":"10.1016\/j.prrv.2019.08.002_b0025","unstructured":"World Health Organization. Genetics and asthma: World Health Organization; [Available from: http:\/\/www.who.int\/genomics\/about\/Asthma.pdf accessed April 4 2018."},{"issue":"11","key":"10.1016\/j.prrv.2019.08.002_b0030","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87632","article-title":"Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life","volume":"1","author":"Davies","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.prrv.2019.08.002_b0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12865-015-0131-y","article-title":"PHF11 expression and cellular distribution is regulated by the toll-like receptor 3 ligand polyinosinic: polycytidylic Acid in HaCaT keratinocytes","volume":"16","author":"Muscat","year":"2015","journal-title":"BMC Immunol"},{"issue":"12","key":"10.1016\/j.prrv.2019.08.002_b0040","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1164\/rccm.2503006","article-title":"Confirmation of GPRA: a putative drug target for asthma","volume":"171","author":"Postma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.prrv.2019.08.002_b0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.anai.2014.12.003","article-title":"Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype","volume":"114","author":"Kim","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.prrv.2019.08.002_b0050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2222.2004.01860.x","article-title":"Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample","volume":"34","author":"Kabesch","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.prrv.2019.08.002_b0055","article-title":"Management of the patient with eosinophilic asthma: a new era begins","author":"de Groot","year":"201511","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.prrv.2019.08.002_b0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thx.2010.135574","article-title":"A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)","volume":"67","author":"Petsky","year":"2012","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.prrv.2019.08.002_b0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","article-title":"High blood eosinophil count is associated with more frequent asthma attacks in asthma patients","volume":"113","author":"Tran","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.prrv.2019.08.002_b0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJM198902023200502","article-title":"Association of asthma with serum IgE levels and skin-test reactivity to allergens","volume":"320","author":"Burrows","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.prrv.2019.08.002_b0075","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaip.2015.12.002","article-title":"Monitoring allergic patients on omalizumab with free and total serum IgE measurements","volume":"4","author":"Hamilton","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.prrv.2019.08.002_b0080","first-page":"120","article-title":"Relationship between serum total IgE and disease severity in patients with allergic asthma in Spain","volume":"25","author":"Davila","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.prrv.2019.08.002_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-015-0019-x","article-title":"Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics","volume":"2","author":"Scichilone","year":"2016","journal-title":"Asthma Res Pract"},{"issue":"3","key":"10.1016\/j.prrv.2019.08.002_b0090","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2016.05.033","article-title":"Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development","volume":"139","author":"Anderson","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.prrv.2019.08.002_b0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12948-017-0064-5","article-title":"Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study","volume":"15","author":"Djuric-Filipovic","year":"2017","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.prrv.2019.08.002_b0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.rmed.2017.01.008","article-title":"Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety","volume":"124","author":"Mansur","year":"2017","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.prrv.2019.08.002_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018186","article-title":"Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre","volume":"7","author":"Demarche","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.prrv.2019.08.002_b0110","article-title":"Exhaled nitric oxide levels to guide treatment for adults with asthma","volume":"9","author":"Petsky","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.prrv.2019.08.002_b0115","article-title":"Exhaled nitric oxide levels to guide treatment for children with asthma","volume":"11","author":"Petsky","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.prrv.2019.08.002_b0120","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.prrv.2019.08.002_b0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.alit.2015.12.006","article-title":"Persistently high exhaled nitric oxide and loss of lung function in controlled asthma","volume":"65","author":"Matsunaga","year":"2016","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.prrv.2019.08.002_b0130","article-title":"Global strategy for asthma management and prevention: GINA executive summary Eur Respir J 2008; 31: 143\u2013178","volume":"51","author":"Bateman","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.prrv.2019.08.002_b0135","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1542\/peds.2012-1147","article-title":"Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children","volume":"130","author":"Zollner","year":"2012","journal-title":"Pediatrics"},{"issue":"1 Pt 2","key":"10.1016\/j.prrv.2019.08.002_b0140","first-page":"e206","article-title":"A randomized trial of lower leg and height growth in children with asthma treated with inhaled budesonide from a new dry powder inhaler","volume":"21","author":"Gradman","year":"2010","journal-title":"Pediatr Allergy Immunol."},{"issue":"1","key":"10.1016\/j.prrv.2019.08.002_b0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13223-015-0075-z","article-title":"CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma","volume":"11","author":"Issa-El-Khoury","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"10.1016\/j.prrv.2019.08.002_b0150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa1710988","article-title":"Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations","volume":"378","author":"Jackson","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.prrv.2019.08.002_b0155","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJMoa1714257","article-title":"Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations","volume":"378","author":"McKeever","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.prrv.2019.08.002_b0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1081-1206(10)60055-5","article-title":"Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients","volume":"100","author":"Naqvi","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.prrv.2019.08.002_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2016.08.001","article-title":"Systemic corticosteroid responses in children with severe asthma: phenotypic and endotypic features","volume":"5","author":"Fitzpatrick","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.prrv.2019.08.002_b0170","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jaci.2018.09.034","article-title":"Integrative approach identifies corticosteroid response variant in diverse populations with asthma","volume":"143","author":"Levin","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.prrv.2019.08.002_b0175","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1542\/peds.2010-1720","article-title":"Age and risks of FDA-approved long-acting beta(2)-adrenergic receptor agonists","volume":"128","author":"McMahon","year":"2011","journal-title":"Pediatrics"},{"issue":"26","key":"10.1016\/j.prrv.2019.08.002_b0180","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1716868","article-title":"Combined analysis of asthma safety trials of long-acting beta2-agonists","volume":"378","author":"Busse","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2019.08.002_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02770903.2013.822081","article-title":"Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities","volume":"51","author":"Pacheco","year":"2014","journal-title":"J Asthma"},{"key":"10.1016\/j.prrv.2019.08.002_b0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40733-016-0026-6","article-title":"Asthma phenotypes: the intriguing selective intervention with Montelukast","volume":"2","author":"Marcello","year":"2016","journal-title":"Asthma Res Pract"},{"issue":"10095","key":"10.1016\/j.prrv.2019.08.002_b0195","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2019.08.002_b0200","article-title":"Macrolides for chronic asthma","volume":"9","author":"Kew","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.prrv.2019.08.002_b0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5114\/ada.2017.71421","article-title":"Seasonal variation of asthma control, lung function tests and allergic inflammation in relation to vitamin D levels: a prospective annual study","volume":"35","author":"Batmaz","year":"2018","journal-title":"Postepy Dermatol Allergol"},{"key":"10.1016\/j.prrv.2019.08.002_b0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijnurstu.2017.04.003","article-title":"Vitamin D for the management of asthma: a Cochrane review summary","volume":"73","author":"Whitehead","year":"2017","journal-title":"Int J Nurs Stud"},{"key":"10.1016\/j.prrv.2019.08.002_b0215","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-3833","article-title":"Allergen-specific immunotherapy in the treatment of pediatric asthma: a systematic review","author":"Rice","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2019.08.002_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.01.058","article-title":"AAAAI\/ACAAI subcutaneous immunotherapy surveillance study (2013\u20132017): fatalities, infections, delayed reactions, and use of epinephrine autoinjectors","author":"Epstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.prrv.2019.08.002_b0225","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: World Allergy Organization position paper 2013 update","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.prrv.2019.08.002_b0230","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"10.1016\/j.prrv.2019.08.002_b0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1479972317709650","article-title":"The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma","volume":"15","author":"Bilocca","year":"2018","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.prrv.2019.08.002_b0240","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40248-016-0065-0","article-title":"Perimenstrual asthma: from pathophysiology to treatment strategies","volume":"11","author":"Graziottin","year":"2016","journal-title":"Multidiscip Respir Med"},{"issue":"3","key":"10.1016\/j.prrv.2019.08.002_b0245","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0091-6749(03)01861-X","article-title":"Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial","volume":"112","author":"Rosenwasser","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"10.1016\/j.prrv.2019.08.002_b0250","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.prrv.2019.08.002_b0255","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"10056","key":"10.1016\/j.prrv.2019.08.002_b0260","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.prrv.2019.08.002_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.prrv.2019.08.002_b0270","article-title":"Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis","author":"Casale","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.prrv.2019.08.002_b0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaci.2014.07.039","article-title":"IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers","volume":"135","author":"Hernandez","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"A7759","key":"10.1016\/j.prrv.2019.08.002_b0280","article-title":"ABM125 anti-IL-25 antibody pre-clinical development for viral asthma exacerbations identifies IL-25 mediated regulation of type-2- and anti-viral immunity","volume":"197","author":"Bartlett","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.prrv.2019.08.002_b0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133774","article-title":"Vaccination against IL-33 inhibits airway hyperresponsiveness and inflammation in a house dust mite model of asthma","volume":"10","author":"Lei","year":"2015","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.prrv.2019.08.002_b0290","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2013.08.009","article-title":"Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma","volume":"132","author":"Wechsler","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.prrv.2019.08.002_b0295","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1378\/chest.127.6.1999","article-title":"A prospective feasibility study of bronchial thermoplasty in the human airway","volume":"127","author":"Miller","year":"2005","journal-title":"Chest"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054219300818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054219300818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:36:27Z","timestamp":1761507387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054219300818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":59,"alternative-id":["S1526054219300818"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2019.08.002","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2019.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}